Pacira to Detail Strategy at Barclays Healthcare Conference
Event summary
- Pacira BioSciences will participate in a fireside chat at the Barclays 28th Annual Global Healthcare Conference.
- The event is scheduled for March 11, 2026, at 2:30 PM ET in Miami.
- A live audio webcast will be available on Pacira's investor relations website.
- Pacira's product portfolio includes EXPAREL®, ZILRETTA®, and iovera®º.
The big picture
Pacira's participation in the Barclays conference signals a continued effort to engage with investors and analysts amidst ongoing scrutiny of the opioid crisis and the demand for alternative pain management solutions. The fireside chat offers a platform to address investor concerns regarding the company's pipeline, market positioning, and long-term growth prospects. The company's valuation will be heavily influenced by the perceived success of its gene therapy program and its ability to maintain market leadership in non-opioid pain therapies.
What we're watching
- Pipeline Progress
- The conference provides an opportunity to assess the progress of PCRX-201, Pacira’s gene therapy candidate, and whether Phase 2 data will support continued development.
- Market Adoption
- How effectively Pacira can articulate the value proposition of its non-opioid therapies will influence adoption rates and ultimately impact revenue growth in a competitive pain management landscape.
- Competitive Landscape
- The discussion will likely reveal the extent to which emerging competitors are impacting Pacira’s market share and pricing power within the regional and specialty anesthesia segments.
Related topics